Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year stint with Elon Musk.

Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The ...

Vertex Pharmaceuticals' top line has grown significantly over the years thanks to the approval of Trikafta in 2019. The company recently obtained approval for a gene therapy treatment, Casgevy. Strong ...